GIM
BCRX icon

Granahan Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Granahan Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-469,430
Closed -$7.63M – 177
2022
Q1 		$7.63M Sell
469,430
-661,148
-58% -$10.6M 0.19% 109
2021
Q4 		$15.7M Buy
1,130,578
+262,658
+30% +$3.48M 0.32% 87
2021
Q3 		$12.5M Buy
867,920
+413,925
+91% +$6.53M 0.24% 100
2021
Q2 		$7.18M Buy
453,995
+24,093
+6% +$327K 0.13% 137
2021
Q1 		$4.37M Buy
+429,902
New +$4.43M 0.09% 149

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Granahan Investment Management's BCRX Position: Q2 2022 in Review

Granahan Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 469,430 shares — an estimated $7.63M sold.

Granahan Investment Management first reported a position in BCRX in Q1 2021 and held it in 5 quarters. The position peaked at $15.7M in Q4 2021. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

  • Granahan Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Granahan Investment Management sold 469,430 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $7.63M.
  • Granahan Investment Management first reported a position in BioCryst Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Granahan Investment Management's BioCryst Pharmaceuticals position peaked at $15.7M in Q4 2021.
  • 221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Granahan Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.